DeepMed Research

ACTAVIS INC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream"

Phase 3

Completed

Conditions: Rosacea

Interventions: Drug: Placebo
Drug: Rhofade Cream, 1%
Drug: Oxymetazoline Hydrochloride

First Posted Date: 2019-05-17

Last Posted Date: 2021-06-23

Lead Sponsor: Actavis Inc.

Target Recruit Count: 1105

Registration Number: NCT03954444

Locations: 🇺🇸
Site 1, Lynchburg, Virginia, United States

Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Fluticasone propionate pressurized metered dose inhaler
Drug: Placebo pressurized metered dose inhaler
Drug: Flovent HFA pressurized metered dose inhaler

First Posted Date: 2019-03-19

Last Posted Date: 2021-09-01

Lead Sponsor: Actavis Inc.

Target Recruit Count: 1902

Registration Number: NCT03879837

Locations: 🇺🇸
Site 1, Spartanburg, South Carolina, United States

Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Fluticasone Propionate and Salmeterol Inhalation Powder
Drug: Placebo Inhalation Powder

First Posted Date: 2018-11-28

Last Posted Date: 2021-09-24

Lead Sponsor: Actavis Inc.

Target Recruit Count: 999

Registration Number: NCT03756883

Locations: 🇺🇸
Study Site 101, Miami Lakes, Florida, United States

Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension

Phase 3

Completed

Conditions: Cataract

Interventions: Drug: Placebos
Drug: Nepafenac 0.3% Oph Susp
Drug: Nepafenac 0.3% Oph Susp (reference)

First Posted Date: 2018-04-17

Last Posted Date: 2021-02-16

Lead Sponsor: Actavis Inc.

Target Recruit Count: 448

Registration Number: NCT03499873

Locations: 🇺🇸
Key-Whitman Eye Center, Dallas, Texas, United States

Clinical Endpoint Study of Ivermectin 0.5% Lotion

Phase 3

Completed

Conditions: Head Lice

Interventions: Drug: Generic Ivermectin Lotion 0.5%
Drug: Vehicle Lotion
Drug: Sklice® (Ivermectin) Lotion 0.5%

First Posted Date: 2017-10-04

Last Posted Date: 2019-12-20

Lead Sponsor: Actavis Inc.

Target Recruit Count: 905

Registration Number: NCT03301649

Locations: 🇺🇸
Site 1, Miami, Florida, United States

Study to Evaluate Equivalence of Estradiol Vaginal Cream 0.01% to Estrace® Cream 0.01% in Atrophic Vaginitis

Phase 3

Completed

Conditions: Atrophic Vaginitis

Interventions: Drug: Estrace® Vaginal Cream USP, 0.01%
Drug: Generic Estradiol Vaginal Cream USP, 0.01%
Drug: Vehicle Vaginal Cream

First Posted Date: 2017-09-27

Last Posted Date: 2019-12-26

Lead Sponsor: Actavis Inc.

Target Recruit Count: 663

Registration Number: NCT03294538

Locations: 🇺🇸
Site Number 22, Savannah, Georgia, United States
🇺🇸
Site Number 29, Roswell, Georgia, United States
🇺🇸
Site Number 16, Kalamazoo, Michigan, United States

and more 41 locations

A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants With Rosacea

Phase 3

Completed

Conditions: Rosacea

Interventions: Drug: Finacea® (Azelaic Acid) Foam
Drug: Generic Azelaic Acid Foam
Drug: Vehicle Foam
Other: Cleanser
Other: Sunscreen
Other: Towel
Other: Moisturizing Lotion

First Posted Date: 2017-09-19

Last Posted Date: 2019-07-31

Lead Sponsor: Actavis Inc.

Target Recruit Count: 924

Registration Number: NCT03287791

Locations: 🇺🇸
Investigative Site 8, High Point, North Carolina, United States
🇺🇸
Investigative Site 5, Norfolk, Virginia, United States
🇺🇸
Investigative Site 21, Philadelphia, Pennsylvania, United States

and more 23 locations

An Equivalence Study of Generic Ingenol Mebutate Gel 0.015% and Picato Gel 0.015% in Subjects With Actinic Keratosis

Phase 3

Completed

Conditions: ACTINIC KERATOSIS

Interventions: Drug: Generic Ingenol Mebutate
Drug: Vehicle Foam
Drug: Ingenol Mebutate (Picato®)

First Posted Date: 2017-06-27

Last Posted Date: 2020-01-14

Lead Sponsor: Actavis Inc.

Target Recruit Count: 507

Registration Number: NCT03200912

Locations: 🇺🇸
Dermatology Associates of Knoxville, PC, Knoxville, Tennessee, United States
🇺🇸
Palmetto Clinical Trial Services, Fountain Inn, South Carolina, United States
🇺🇸
Northwest Clinical Trials, Inc., Boise, Idaho, United States

and more 20 locations

Clinical Endpoint Study of Ivermectin 1% Cream

Phase 3

Completed

Conditions: Moderate to Severe Papulopustular Rosacea

Interventions: Drug: Ivermectin Cream, 1%
Drug: Placebo/Vehicle cream

First Posted Date: 2016-07-21

Last Posted Date: 2020-06-02

Lead Sponsor: Actavis Inc.

Target Recruit Count: 630

Registration Number: NCT02840461

Locations: 🇺🇸
Investigator site 1, Arlington Heights, Illinois, United States

Study of Equivalence of Generic Pimecrolimus Cream 1% and Elidel® 1% in Subjects With Mild to Moderate Atopic Dermatitis

Phase 3

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Pimecrolimus Cream, 1%
Drug: Vehicle cream
Drug: Pimecrolimus Cream 1% (Valeant)

First Posted Date: 2016-06-06

Last Posted Date: 2020-05-29

Lead Sponsor: Actavis Inc.

Target Recruit Count: 587

Registration Number: NCT02791308

Locations: 🇺🇸
Pflugerville Dermatology Clinical Research Center, Inc., Pflugerville, Texas, United States
🇺🇸
International Clinical Research- US, LLC, Sanford, Florida, United States
🇺🇸
MD Studies, Inc., Fountain Valley, California, United States

and more 49 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy